Managing Complex Hypertension: What Every Physician Should Know

Slides:

Advertisements

Similar presentations

ASCOT ASCOT STUDY. ASCOT INTRODUCTION AND AIMS EXISTING KNOWLEDGE BACKGROUND OF ASCOT STUDY DESIGN (TWO ARMS (BPLA,LLA) METHODOLOGY TREATMENT REGIMES.

Advertisements

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Hypertension in the Elderly

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

Thiazide-Like/Calcium Channel Blocker (CCB) Agents: A Major Combination for Hypertension Management Safar M, Blacher J. Am J Cardiovasc Drugs. 2014; DOI.

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.

Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.

LEADER trial: Primary Outcome

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

The Anglo Scandinavian Cardiac Outcomes Trial

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?

CV Risk reduction in T2DM with GLP-1 Agonists: Should We Change Our Clinical Practice?

CV Risk Management in T2DM: What Did We Learn From EASD 2016?

Select Topics in Cardiovascular Medicine

Section VIII. Ambulatory BP Measurement

New Insights Into Neurogenic Orthostatic Hypotension

Can Primary Care Physicians Take the Lead in Combating Obesity?

How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients

Resistant Hypertension

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Novel Developments & Latest Clinical Results With Long-Acting GLP-1 Receptor Agonists.

Strategies to Improve Adherence and Persistence in the Treatment of Hypertension.

Hypertension Guidelines

Latest Cardiovascular Outcomes Trials: A Closer Look at the LEADER Results.

Impacting CV Risk With Diabetes Medications

Blood pressure control: dependence on adherence

CV Outcome Studies Empa-reg Leader Pio Stroke (Proactive) Bromocriptine Metformin-UKPDS.

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Impacting CV Risk With Diabetes Medications

A Deep Dive Into CVOTs.

Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.

A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.

The future of urate-lowering strategies for gout

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Tackling CV Risk in T2DM.

Evaluating New Therapies in HF

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

LEADER One Year On.

GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

T2DM, CV Risk, and Modulating Risk With Glucose-Lowering Strategies

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

2015 EASD In Review: CV Risk management in t2dm

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Improving Management of Acute HTN in Patients With Stroke

The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?

Presentation transcript:

Managing Complex Hypertension: What Every Physician Should Know

Introduction/Background

ESH/ESC/JNC8 Blood Pressure Treatment Recommendations

Complex Hypertension: Hard-to-Treat and/or With Comorbidities

Results From The SPRINT Trial: SBP >130? >120?

Controversy Surrounding BP Measurement in SPRINT

The J-Curve and Risk of Aggressive Blood Pressure Reduction

Early, Aggressive Treatment of HTN?

Non-Adherence to Antihypertensive Agents: Results of a Urine-Based Assay

Single-Pill Combinations vs Free Drug Components: Effects on Compliance

The Treatment-Resistant Hypertensive Patient

(Apparent) Resistant HTN Patients With Appropriate Triple Therapy

Non-Adherence and the Older Hypertensive Patient

Improving Adherence to Therapy: Patient Communication Strategies

Medical Complications of Hypertension

End-Organ Damage Associated With Chronic Hypertension

The Cardiovascular-Renal Continuum in The Context of Hypertension

Prevalence of HTN in Selected AF Trials

Antihypertensive Single-Pill Combination Therapy Compared to Monotherapy and Placebo: A Subgroup Analysis

Current Dosages of Hydrochlorothiazide for HTN May Be Suboptimal

Superior BP Reduction With Initial Combination Therapy

Initial Combination HTN Therapy Reduces CV Event Rates

LEADER: Primary Outcome Liraglutide vs Placebo*

EMPA-REG: Primary Outcome (3-Point MACE) CV Death, Nonfatal MI, or Nonfatal Stroke

Summary and Conclusions

Abbreviations

Abbreviations (cont)